Search and Browse
Download
Enter Data
| Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM398261 (4-Chloro-1-dimethylcarbamoylmethyl-1H-indole-3-car...) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM398157 (4-chloro-N-(((1R,3R)-1-hydroxy-3-methylcyclohexyl)...) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| hIL-1beta (Homo sapiens (Human)) | BDBM398233 (4-chloro-N-((4,4-difluorocyclohexyl)methyl)-1-(pip...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM398147 (4-chloro-N-((1-hydroxy-3-methylcyclohexyl)methyl)-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| hIL-1beta (Homo sapiens (Human)) | BDBM398219 (4-chloro-N-((3,3-difluoro-5-methylcyclohexyl)methy...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM398233 (4-chloro-N-((4,4-difluorocyclohexyl)methyl)-1-(pip...) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| hIL-1beta (Homo sapiens (Human)) | BDBM398117 (4-chloro-1-(oxetan-3-yl)-N-((1-(4-phenylpiperazin-...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM398141 (4-Chloro-1-oxetan-3-yl-1H-indole-3-carboxylic acid...) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM398259 (4-chloro-N-((4, 4-difluorocyclohexyl)methyl)-1-(1-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| hIL-1beta (Homo sapiens (Human)) | BDBM398106 (Preparations of 4-chloro-N-((4,4-difluorocyclohexy...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM398134 (4-chloro-1-(oxetan-3-yl)-N-(spiro[2.5]octan-5-ylme...) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| hIL-1beta (Homo sapiens (Human)) | BDBM398218 (4-chloro-N-((3,3-difluorocyclohexyl)methyl)-1-(pyr...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM398263 (4-Chloro-1-dimethylcarbamoylmethyl-1H-indole-3-car...) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| hIL-1beta (Homo sapiens (Human)) | BDBM398217 (4-chloro-N-((3, 3-difluoro-1-hydroxycyclohexyl)met...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM450521 (US10676433, Compound 153) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM450448 (US10676433, Compound 158 | US10676433, Compound 76) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| hIL-1beta (Homo sapiens (Human)) | BDBM450448 (US10676433, Compound 158 | US10676433, Compound 76) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM398071 (US10323000, Compound 7 | US10676433, Compound 7) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM398073 (4-Chloro-1-(3,3-difluoro-propyl)-1H-indole-3-carbo...) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM398085 ((R)-4-chloro-N-((3,3-difluoro-1-hydroxycyclohexyl)...) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM398146 (4-Chloro-1-oxetan-3-yl-1H-indole-3-carboxylic acid...) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM398154 (Preparations of 4-chloro-N-(((1S,3S)-1-hydroxy-3-m...) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM450530 (US10676433, Compound 163) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM398102 (4-chloro-N-((4,4-difluorocyclohexyl)methyl)-1-(3,3...) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 55 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM398253 (4-chloro-N-((4,4-difluorocyclohexyl)methyl)-1-(2-(...) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 55 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM398254 (4-Chloro-1-(2-oxo-2-piperidin-1-yl-ethyl)-1H-indol...) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 55 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM398104 (4-chloro-1-(2-methoxyethyl)-N-((1-phenylcyclohexyl...) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 55 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM398105 (4-chloro-N-((4,4-difluoro-1-hydroxycyclohexyl)meth...) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 55 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| hIL-1beta (Homo sapiens (Human)) | BDBM398147 (4-chloro-N-((1-hydroxy-3-methylcyclohexyl)methyl)-...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 55 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| hIL-1beta (Homo sapiens (Human)) | BDBM398158 (4-chloro-N-((4,4-difluorocyclohexyl)methyl)-1-(oxe...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 55 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| hIL-1beta (Homo sapiens (Human)) | BDBM398176 (4-chloro-N-(((1R,3R)-1-hydroxy-3-methyl cyclohexyl...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 55 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| hIL-1beta (Homo sapiens (Human)) | BDBM450487 (US10676433, Compound 118) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | UniChem | US Patent | n/a | n/a | 55 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM450490 (US10676433, Compound 121) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | UniChem | US Patent | n/a | n/a | 55 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM398194 ((R)-4-chloro-N-((4,4-difluoro-1-hydroxycyclohexyl)...) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 55 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM398221 (4-chloro-N-((3, 3-difluoro-1-hydroxycyclohexyl)met...) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 55 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM398234 (4-chloro-N-((4, 4-difluorocyclohexyl)methyl)-1-(pi...) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 55 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM398242 ((R)-4-chloro-N-((4, 4-difluorocyclohexyl)methyl)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 55 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM398249 (4-chloro-N-((4, 4-difluorocyclohexyl)methyl)-1-(2-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 55 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM398068 (4-chloro-N-((4,4-difluoro-1-hydroxycyclohexyl) met...) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 55 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM450410 (US10676433, Compound 38) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | UniChem | US Patent | n/a | n/a | 55 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM398255 (4-chloro-N-((4,4-difluorocyclohexyl)methyl)-1-((1-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 55 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| hIL-1beta (Homo sapiens (Human)) | BDBM398259 (4-chloro-N-((4, 4-difluorocyclohexyl)methyl)-1-(1-...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 55 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| hIL-1beta (Homo sapiens (Human)) | BDBM398105 (4-chloro-N-((4,4-difluoro-1-hydroxycyclohexyl)meth...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 55 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM398125 (4-Chloro-1-oxetan-3-yl-1H-indole-3-carboxylic acid...) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 55 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM398128 (4-Chloro-1-oxetan-3-yl-1H-indole-3-carboxylic acid...) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 55 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM398133 (4-chloro-N—(((S)-3, 3-difluorocyclohexyl)meth...) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 55 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| hIL-1beta (Homo sapiens (Human)) | BDBM398133 (4-chloro-N—(((S)-3, 3-difluorocyclohexyl)meth...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 55 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM398158 (4-chloro-N-((4,4-difluorocyclohexyl)methyl)-1-(oxe...) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 55 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM398177 (4-chloro-N-((4, 4-difluorocyclohexyl)methyl)-1-(te...) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 55 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor.... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| hIL-1beta (Homo sapiens (Human)) | BDBM398179 (US10323000, Compound 116 | US10676433, Compound 11...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 55 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Patent GmbH US Patent | Assay Description The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a... | US Patent US10676433 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Displayed 1 to 50 (of 355 total ) | Next | Last >> |
